Takeda

News

Takeda to sell dry eye drug to Novartis for up to $5.3bn

Takeda has announced it is to sell the dry eye drug Xiidra to Novartis, and a surgical patch to Johnson & Johnson, for a potential total of $5.7 billion as it seeks to pay off debts fol

News

NICE backs interim funding for J&J/Takeda myeloma regimen

A three-drug regimen for multiple myeloma based on Johnson & Johnson’s Darzalex, Takeda’s Velcade and dexamethasone will be made available to patients in England, but only via the Cance

News

Takeda's Entyvio outperforms AbbVie's Humira in GI trial

Takeda has announced results from its gastro drug Entyvio, showing that it largely outperformed the industry standard – AbbVie’s Humira – in severely active ulcerative colitis.

News

Takeda mulling sale of emerging market drugs - report

Takeda could be considering selling some emerging-market drugs in a bid to cut debts following its merger with Shire that completed earlier this month, according to a press report.

News

Takeda's Shire takeover could herald new era of pharma M&A

Takeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in big pharma.

News

Takeda unlikely to sell OTC unit to pay Shire merger debts

Takeda’s $59 billion takeover of Shire is due to close tomorrow (Tuesday) and the company’s CEO Christophe Weber has already given some strong clues about the company’s strategy once the de

Takeda to sell dry eye drug to Novartis for up to $5.3bn

NICE backs interim funding for J&J/Takeda myeloma regimen

Takeda's Entyvio outperforms AbbVie's Humira in GI trial

Takeda mulling sale of emerging market drugs - report

Takeda's Shire takeover could herald new era of pharma M&A

Takeda unlikely to sell OTC unit to pay Shire merger debts

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

Takeda

Editor's Picks